Table 1.
Baseline characteristics of 1279 advanced LC patients with and without DM.
| Variable | All | Non-DM | DM | P value* | DM patients | P value# | ||
|---|---|---|---|---|---|---|---|---|
| Low tertile (HbA1c: 4.5-5.7) | Middle tertile (HbA1c: 5.8-6.1) | High tertile (HbA1c: 6.2-10.7) | ||||||
| No. of patients | 1279 | 979 | 300 | / | 88 | 93 | 119 | / |
| Age (mean± SD), y | 58.89 ± 10.71 | 59.08 ± 10.64 | 58.25 ± 10.90 | 0.238 | 51.91 ± 11.52 | 58.99 ± 8.65 a | 62.36 ± 9.86ab | <0.001 |
| Age | 0.933 | <0.001 | ||||||
| ≤65 | 880 (68.80%) | 673 (68.74%) | 207 (69.00%) | 76 (86.36%) | 68 (73.12%) | 63 (52.94%)ab | ||
| >65 | 399 (31.20%) | 306 (31.26%) | 93 (31.00%) | 12 (13.64%) | 25 (26.88%) | 56 (47.06%) | ||
| BMI at baseline, kg/m2 | 22.48 ± 3.03 | 22.36 ± 3.03 | 22.85 ± 3.00 | 0.016 | 21.82 ± 2.81 | 22.97 ± 3.08 a | 23.51 ± 2.89 a | <0.001 |
| BMI | 0.006 | <0.001 | ||||||
| ≤24 | 887 (69.35%) | 698 (71.30%) | 189 (63.00%) | 69 (78.41%) | 62 (66.67%) | 58 (48.74%)ab | ||
| >24 | 392 (30.65%) | 281 (28.70%) | 111 (37.00%) | 19 (21.59%) | 31 (33.33%) | 61 (51.26%) | ||
| Sex | 0.400 | <0.001 | ||||||
| Male | 760 (59.42%) | 588 (60.06%) | 172 (57.33%) | 36 (40.91%) | 50 (53.76%) | 86 (72.27%)ab | ||
| Female | 519 (40.58%) | 391 (39.94%) | 128 (42.67%) | 52 (59.09%) | 43 (46.24%) | 33 (27.73%) | ||
| Smoking history | 0.647 | <0.001 | ||||||
| Non-smoker | 740 (57.86%) | 563 (57.51%) | 177 (59.00%) | 66 (75.00%) | 58 (62.37%) | 53 (44.54%)ab | ||
| Ever smoker | 539 (42.14%) | 416 (42.49%) | 123 (41.00%) | 22 (25.00%) | 35 (37.63%) | 66 (55.46%) | ||
| CVD | <0.001 | 0.001 | ||||||
| Without CVD | 1032 (80.69%) | 861 (87.95%) | 171 (57.00%) | 62 (70.45%) | 55 (59.14%) | 54 (45.38%) a | ||
| With CVD | 247 (19.31%) | 118 (12.05%) | 129 (43.00%) | 26 (29.55%) | 38 (40.86%) | 65 (54.62%) | ||
| Stage | 0.628 | 0.432 | ||||||
| IIIB | 497 (38.86%) | 384 (39.22%) | 113 (37.67%) | 38 (43.18%) | 32 (34.41%) | 43 (36.13%) | ||
| IV | 782 (61.14%) | 595 (60.78%) | 187 (62.33%) | 50 (56.82%) | 61 (65.59%) | 76 (63.87%) | ||
| EGFR | 0.637 | <0.001 | ||||||
| Wildtype | 620 (48.48%) | 471 (48.11%) | 149 (49.67%) | 29 (32.95%) | 43 (46.24%) | 77 (64.71%)ab | ||
| Mutated | 659 (51.52%) | 508 (51.89%) | 151 (50.33%) | 59 (67.05%) | 50 (53.76%) | 42 (35.29%) | ||
| Histology | 0.064 | <0.001 | ||||||
| Adenocarcinoma | 976 (76.31%) | 759 (77.53%) | 217 (72.33%) | 73 (82.95%) | 74 (79.57%) | 70 (58.82%)ab | ||
| Non-Adenocarcinoma | 303 (23.69%) | 220 (22.47%) | 83 (27.67%) | 15 (17.05%) | 19 (20.43%) | 49 (41.18%) | ||
| First-line treatment | 0.005 | 0.007 | ||||||
| EGFR-TKIs | 496 (38.78%) | 397 (40.55%) | 99 (33.00%) | 37 (42.05%) | 35 (37.63%) | 27 (22.69%) a | ||
| Chemotherapy/chemoradiotherapy | 769 (60.13%) | 568 (58.02%) | 201 (67.00%) | 51 (57.95%) | 58 (62.37%) | 92 (77.31%) | ||
| Others | 14 (1.09%) | 14 (1.43%) | 0 (0) | / | / | / | ||
| De novo advanced NSCLC | 0.794 | 0.655 | ||||||
| Yes | 1094 (85.54%) | 836 (85.39%) | 258 (86.00%) | 74 (84.09%) | 79 (84.95%) | 105 (88.24%) | ||
| No | 185 (14.46%) | 143 (14.61%) | 42 (14.00%) | 14 (15.91%) | 14 (15.05%) | 14 (11.76%) | ||
DM, diabetes; CVD, cardiovascular disease; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitors.
*compared between patients with and without DM.
#compared among DM patients categorized into low, middle, and high tertiles according to the HbA1c level.
a
P<0.05 compared with the low tertile group.
b
P<0.05 compared with the middle tertile group.